Imprime PGG is an immunomodulatory drug, used as a treatment for cancer.
The open label multicentre randomised trial involving 90 patients assessed the safety and efficacy of Imprime PGG along with cetuximab and a standard chemotherapy regimen (carboplatin and paclitaxel) compared to cetuximab alone with the same chemotherapy.
The study intended to determine the anti-tumour effects of Imprime PGG with cetuximab and standard chemotherapy, based on overall response rate as evaluated by Response Evaluation Criteria in Solid Tumors (RECIST).
Imprime PGG, at present is being studied in a Phase III trial in KRAS wild type colorectal cancer and several Phase II clinical trials in non-small cell lung cancer and chronic lymphocytic leukemia.